CompletedNCT00378092
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
Medication studyAges 17–47South AfricaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 17 years to 47 years.
- Listed locations
- BellvilleSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- Janssen Cilag N.V./S.A.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Africa
- Age range
- From 17 Years to 47 Years
- Official registry ID
- NCT00378092
- Official title
Show the full official title
A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia
Recruitment & locations
CompletedBellville
Questions about this study
Who is behind this study?
The study sponsor is Janssen Cilag N.V./S.A.
Did this study involve medication?
Yes. The study involved medication, including Oral risperidone and Risperidone Long-Acting Injection (RLAI).
Who was this study for?
Listed age limits: 17 years to 47 years.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit me